Suppr超能文献

生长激素过多和生长激素缺乏症中的心血管系统。

The cardiovascular system in growth hormone excess and growth hormone deficiency.

机构信息

Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy.

出版信息

J Endocrinol Invest. 2012 Dec;35(11):1021-9. doi: 10.3275/8717. Epub 2012 Nov 12.

Abstract

The clinical conditions associated with GH excess and GH deficiency (GHD) are known to be associated with an increased risk for the cardiovascular morbidity and mortality, suggesting that either an excess or a deficiency in GH and/or IGF-I is deleterious for cardiovascular system. In patients with acromegaly, chronic GH and IGF-I excess commonly causes a specific cardiomyopathy characterized by a concentric cardiac hypertrophy associated with diastolic dysfunction and, in later stages, with systolic dysfunction ending in heart failure if GH/IGF-I excess is not controlled. Abnormalities of cardiac rhythm and anomalies of cardiac valves can also occur. Moreover, the increased prevalence of cardiovascular risk factors, such as hypertension, diabetes mellitus, and insulin resistance, as well as dyslipidemia, confer an increased risk for vascular atherosclerosis. Successful control of the disease is accompanied by a decrease of the cardiac mass and improvement of cardiac function and an improvement in cardiovascular risk factors. In patients with hypopituitarism, GHD has been considered the under- lying factor of the increased mortality when appropriate standard replacement of the pituitary hormones deficiencies is given. Either childhood-onset or adulthood-onset GHD are characterized by a cluster of abnormalities associated with an increased cardiovascular risk, including altered body composition, unfavorable lipid profile, insulin resistance, endothelial dysfunction and vascular atherosclerosis, a decrease in cardiac mass together with an impairment of systolic function mainly after exercise. Treatment with recombinant GH in patients with GHD is followed by an improvement of the cardiovascular risk factors and an increase in cardiac mass together with an improvement in cardiac performance. In conclusion, acromegaly and GHD are associated with an increased risk for cardiovascular morbidity and mortality, but the control of GH/IGF-I secretion reverses cardiovascular abnormalities and restores the normal life expectancy.

摘要

与 GH 过多和 GH 缺乏(GHD)相关的临床情况已知与心血管发病率和死亡率增加相关,这表明 GH 和/或 IGF-I 的过多或缺乏对心血管系统都是有害的。在肢端肥大症患者中,慢性 GH 和 IGF-I 过多通常会导致一种特定的心肌病,其特征为同心性心肌肥厚,伴有舒张功能障碍,在后期则伴有收缩功能障碍,如果 GH/IGF-I 过多得不到控制,则会导致心力衰竭。心律失常和心脏瓣膜异常也可能发生。此外,心血管危险因素(如高血压、糖尿病和胰岛素抵抗以及血脂异常)的患病率增加,增加了血管粥样硬化的风险。成功控制疾病伴随着心脏质量的降低、心脏功能的改善以及心血管危险因素的改善。在垂体功能减退症患者中,GHD 被认为是死亡率增加的潜在因素,只要适当替代垂体激素缺乏症即可。儿童期或成年期开始的 GHD 均具有与心血管风险增加相关的一系列异常,包括身体成分改变、不良的血脂谱、胰岛素抵抗、内皮功能障碍和血管粥样硬化、心脏质量降低以及主要在运动后收缩功能受损。在 GHD 患者中使用重组 GH 治疗可改善心血管危险因素、增加心脏质量并改善心脏功能。总之,肢端肥大症和 GHD 与心血管发病率和死亡率增加相关,但控制 GH/IGF-I 分泌可逆转心血管异常并恢复正常预期寿命。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验